Twist Bioscience (TWST) Common Equity (2017 - 2026)

Twist Bioscience (TWST) has 10 years of Common Equity data on file, last reported at $455.1 million in Q1 2026.

• Common Equity for Q1 2026 came in at $455.1 million, up 3.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $455.1 million (up 3.41% YoY), and the FY2025 annual result was $473.0 million, changed 0.06% from the prior year.
• Common Equity was little changed at $455.1 million in Q1 2026 per TWST's latest filing, from $456.1 million in the prior quarter.
• Over five years, Common Equity peaked at $863.4 million in Q1 2022 and troughed at $440.1 million in Q1 2025.
• A 5-year average of $592.8 million and a median of $560.1 million in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2024: Common Equity soared 40.57% in 2022, then slipped 25.31% in 2024.
• A 5-year view of Common Equity shows it stood at $746.3 million in 2022, then fell by 20.94% to $590.0 million in 2023, then declined by 22.73% to $455.9 million in 2024, then advanced by 0.03% to $456.1 million in 2025, then slipped by 0.22% to $455.1 million in 2026.
• Business Quant data shows TWST's Common Equity at $455.1 million in Q1 2026, $456.1 million in Q4 2025, and $473.0 million in Q3 2025.